Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.
Galina A MarkovaNatalia V DemidovaGalina A MarkovaElena A TaskinaSvetlana I GlukhovaDmitry E KarateevPublished in: International journal of rheumatic diseases (2017)
Our results suggest that the expressions of MMP-9 and ULK1 might be associated with disease activity. Increased baseline gene expressions of RUNX2, p21 and caspase 3 in the peripheral blood might predict better responses to MTX therapy.
Keyphrases
- rheumatoid arthritis patients
- disease activity
- peripheral blood
- rheumatoid arthritis
- systemic lupus erythematosus
- ankylosing spondylitis
- cell death
- transcription factor
- genome wide
- copy number
- juvenile idiopathic arthritis
- genome wide identification
- induced apoptosis
- gene expression
- high dose
- emergency department
- signaling pathway
- drug induced
- bone marrow
- cell migration
- smoking cessation
- endoplasmic reticulum stress